Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12755
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIrani, Vashtien
dc.contributor.authorGuy, Andrew Jen
dc.contributor.authorAndrew, Deanen
dc.contributor.authorBeeson, James Gen
dc.contributor.authorRamsland, Paul Aen
dc.contributor.authorRichards, Jack Sen
dc.date.accessioned2015-05-16T02:29:34Z-
dc.date.available2015-05-16T02:29:34Z-
dc.date.issued2015-04-18en
dc.identifier.citationMolecular Immunology 2015; 67(2 Pt A): 171-82en
dc.identifier.govdoc25900877en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12755en
dc.description.abstractMonoclonal antibodies are being developed as therapeutics to complement drugs and vaccines or to fill the gap where no drugs or vaccines exist. These therapeutic antibodies (ThAb) may be especially important for infectious diseases in which there is antibiotic resistance, toxin-mediated pathogenesis, or for emerging pathogens. The unique structure of antibodies determines the specific nature of the effector function, so when developing ThAb, the desired effector functions need to be considered and integrated into the design and development processes to ensure maximum efficacy and safety. Antibody subclass is a critical consideration, but it is noteworthy that almost all ThAb that are licenced or currently in development utilise an IgG1 backbone. This review outlines the major structural properties that vary across subclasses, how these properties affect functional immunity, and discusses the various approaches used to study subclass responses to infectious diseases. We also review the factors associated with the selection of antibody subclasses when designing ThAb and highlight circumstances where different subclass properties might be beneficial when applied to particular infectious diseases. These approaches are critical to the future design of ThAb and to the study of naturally-acquired and vaccine-induced immunity.en
dc.language.isoenen
dc.subject.otherAntibody-dependent effector mechanismsen
dc.subject.otherIgG subclassesen
dc.subject.otherInfectious diseasesen
dc.subject.otherTherapeutic antibodiesen
dc.titleMolecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases.en
dc.typeJournal Articleen
dc.identifier.journaltitleMolecular immunologyen
dc.identifier.affiliationDepartment of Medicine at Royal Melbourne Hospital, University of Melbourne, Parkville, VIC 3050, Australiaen
dc.identifier.affiliationDepartment of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Immunology, Monash University, Alfred Medical Research and Education Precinct, Melbourne, VIC 3004, Australiaen
dc.identifier.affiliationCentre for Biomedical Research, Burnet Institute, Melbourne, VIC 3004, Australiaen
dc.identifier.affiliationSchool of Biomedical Sciences, CHIRI Biosciences, Curtin University, Perth, WA 6845, Australiaen
dc.identifier.affiliationDepartment of Microbiology, Monash University, Clayton, VIC 3800, Australiaen
dc.identifier.doi10.1016/j.molimm.2015.03.255en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25900877en
dc.type.austinJournal Articleen
local.name.researcherRamsland, Paul A
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptSurgery (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.